Supernus Pharmaceuticals Inc Cash Flow Conversion Efficiency
Supernus Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Supernus Pharmaceuticals Inc (SUPN) has a cash flow conversion efficiency ratio of -0.005x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.81 Million) by net assets ($1.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Supernus Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Supernus Pharmaceuticals Inc (2008–2025)
Cash flow conversion efficiency of Supernus Pharmaceuticals Inc from 2008 to 2025. This chart illustrates how Supernus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Supernus Pharmaceuticals Inc (SUPN) share price today for real-time trading data and today's change.
Supernus Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Supernus Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Supernus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Supernus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review Supernus Pharmaceuticals Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voltronic Power Technology Corp
TW:6409
|
0.046x |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
0.024x |
|
North Navigation Control Technology Co Ltd
SHG:600435
|
0.006x |
|
Hanon Systems
KO:018880
|
0.054x |
|
People.Cn Co Ltd
SHG:603000
|
0.020x |
|
Enerflex Ltd.
NYSE:EFXT
|
0.028x |
|
Inari Amertron Bhd
KLSE:0166
|
0.027x |
|
P/F Bakkafrost
F:6BF
|
0.040x |
Annual Cash Flow Conversion Efficiency for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Supernus Pharmaceuticals Inc from 2008 to 2025. Also see Supernus Pharmaceuticals Inc total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.06 Billion | $47.33 Million | 0.045x | -73.15% |
| 2024-12-31 | $1.04 Billion | $171.95 Million | 0.166x | +37.72% |
| 2023-12-31 | $921.52 Million | $111.08 Million | 0.121x | -8.56% |
| 2022-12-31 | $886.20 Million | $116.83 Million | 0.132x | -15.40% |
| 2021-12-31 | $815.85 Million | $127.13 Million | 0.156x | -16.14% |
| 2020-12-31 | $744.86 Million | $138.40 Million | 0.186x | -22.70% |
| 2019-12-31 | $595.43 Million | $143.13 Million | 0.240x | -15.57% |
| 2018-12-31 | $453.02 Million | $128.99 Million | 0.285x | -33.57% |
| 2017-12-31 | $267.48 Million | $114.64 Million | 0.429x | +23.01% |
| 2016-12-31 | $191.75 Million | $66.81 Million | 0.348x | +28.94% |
| 2015-12-31 | $118.88 Million | $32.12 Million | 0.270x | +149.34% |
| 2014-12-31 | $71.35 Million | $7.73 Million | 0.108x | +106.26% |
| 2013-12-31 | $33.46 Million | $-57.95 Million | -1.732x | -111.22% |
| 2012-12-31 | $57.57 Million | $-47.20 Million | -0.820x | +78.60% |
| 2011-12-31 | $9.44 Million | $-36.19 Million | -3.832x | -621.85% |
| 2010-12-31 | $-44.32 Million | $-32.54 Million | 0.734x | +271.61% |
| 2009-12-31 | $-6.16 Million | $2.63 Million | -0.428x | -109.74% |
| 2008-12-31 | $-6.75 Million | $-29.65 Million | 4.395x | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more